Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts.

Delgado-Calle J, Kurihara N, Atkinson EG, Nelson J, Miyagawa K, Galmarini CM, Roodman GD, Bellido T.

Oncotarget. 2019 Apr 12;10(28):2709-2721. doi: 10.18632/oncotarget.26831. eCollection 2019 Apr 12.

2.

The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability.

Tumini E, Herrera-Moyano E, San Martín-Alonso M, Barroso S, Galmarini CM, Aguilera A.

Mol Cancer Res. 2019 Mar;17(3):773-782. doi: 10.1158/1541-7786.MCR-18-0575. Epub 2018 Dec 14.

3.

Binding of eEF1A2 to the RNA-dependent protein kinase PKR modulates its activity and promotes tumour cell survival.

Losada A, Muñoz-Alonso MJ, Martínez-Díez M, Gago F, Domínguez JM, Martínez-Leal JF, Galmarini CM.

Br J Cancer. 2018 Nov;119(11):1410-1420. doi: 10.1038/s41416-018-0336-y. Epub 2018 Nov 13.

4.

ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.

Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA, Galmarini CM, Núñez R, Kahatt C, Paz-Ares L.

Future Oncol. 2019 Jan;15(3):231-239. doi: 10.2217/fon-2018-0597. Epub 2018 Oct 26.

PMID:
30362375
5.

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.

Cruz C, Llop-Guevara A, Garber JE, Arun BK, Pérez Fidalgo JA, Lluch A, Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Pérez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmaña J, Isakoff SJ.

J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21. Erratum in: J Clin Oncol. 2018 Nov 20;36(33):3348. J Clin Oncol. 2019 Feb 1;37(4):362.

6.

Molecular basis of resistance to the microtubule-depolymerizing antitumor compound plocabulin.

Pantazopoulou A, Galmarini CM, Peñalva MA.

Sci Rep. 2018 Jun 5;8(1):8616. doi: 10.1038/s41598-018-26736-3.

7.

MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding In Vivo Activity against HER2-Expressing Tumors.

Avilés P, Domínguez JM, Guillén MJ, Muñoz-Alonso MJ, Mateo C, Rodriguez-Acebes R, Molina-Guijarro JM, Francesch A, Martínez-Leal JF, Munt S, Galmarini CM, Cuevas C.

Mol Cancer Ther. 2018 Apr;17(4):786-794. doi: 10.1158/1535-7163.MCT-17-0795. Epub 2018 Feb 13.

8.

Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells.

Galmarini CM, Martin M, Bouchet BP, Guillen-Navarro MJ, Martínez-Diez M, Martinez-Leal JF, Akhmanova A, Aviles P.

BMC Cancer. 2018 Feb 7;18(1):164. doi: 10.1186/s12885-018-4086-2.

9.

Dynamic cellular maps of molecular species: Application to drug-target interactions.

García C, Losada A, Sacristán MA, Martínez-Leal JF, Galmarini CM, Lillo MP.

Sci Rep. 2018 Jan 18;8(1):1140. doi: 10.1038/s41598-018-19694-3.

10.

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.

Belgiovine C, Bello E, Liguori M, Craparotta I, Mannarino L, Paracchini L, Beltrame L, Marchini S, Galmarini CM, Mantovani A, Frapolli R, Allavena P, D'Incalci M.

Br J Cancer. 2017 Aug 22;117(5):628-638. doi: 10.1038/bjc.2017.205. Epub 2017 Jul 6.

11.

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.

Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, García-Macías MDC, Sevillano V, Alonso D, Pascual-Pasto G, San-Segundo L, Vila-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J, de Álava E.

Oncotarget. 2017 Jun 27;8(26):43592. doi: 10.18632/oncotarget.18610. No abstract available.

12.

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.

Poveda A, Del Campo JM, Ray-Coquard I, Alexandre J, Provansal M, Guerra Alía EM, Casado A, Gonzalez-Martin A, Fernández C, Rodriguez I, Soto A, Kahatt C, Fernández Teruel C, Galmarini CM, Pérez de la Haza A, Bohan P, Berton-Rigaud D.

Ann Oncol. 2017 Jun 1;28(6):1280-1287. doi: 10.1093/annonc/mdx111.

13.

Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.

Uboldi S, Craparotta I, Colella G, Ronchetti E, Beltrame L, Vicario S, Marchini S, Panini N, Dagrada G, Bozzi F, Pilotti S, Galmarini CM, D'Incalci M, Gatta R.

BMC Cancer. 2017 Feb 6;17(1):107. doi: 10.1186/s12885-017-3091-1.

14.

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.

Romano M, Della Porta MG, Gallì A, Panini N, Licandro SA, Bello E, Craparotta I, Rosti V, Bonetti E, Tancredi R, Rossi M, Mannarino L, Marchini S, Porcu L, Galmarini CM, Zambelli A, Zecca M, Locatelli F, Cazzola M, Biondi A, Rambaldi A, Allavena P, Erba E, D'Incalci M.

Br J Cancer. 2017 Jan;116(3):335-343. doi: 10.1038/bjc.2016.424. Epub 2017 Jan 10.

15.

Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.

Harlow ML, Maloney N, Roland J, Guillen Navarro MJ, Easton MK, Kitchen-Goosen SM, Boguslawski EA, Madaj ZB, Johnson BK, Bowman MJ, D'Incalci M, Winn ME, Turner L, Hostetter G, Galmarini CM, Aviles PM, Grohar PJ.

Cancer Res. 2016 Nov 15;76(22):6657-6668. doi: 10.1158/0008-5472.CAN-16-0568. Epub 2016 Oct 3.

16.

Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.

Céspedes MV, Guillén MJ, López-Casas PP, Sarno F, Gallardo A, Álamo P, Cuevas C, Hidalgo M, Galmarini CM, Allavena P, Avilés P, Mangues R.

Dis Model Mech. 2016 Dec 1;9(12):1461-1471. Epub 2016 Oct 20.

17.

Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin.

Losada A, Muñoz-Alonso MJ, García C, Sánchez-Murcia PA, Martínez-Leal JF, Domínguez JM, Lillo MP, Gago F, Galmarini CM.

Sci Rep. 2016 Oct 7;6:35100. doi: 10.1038/srep35100.

18.

Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells.

Santamaría Nuñez G, Robles CM, Giraudon C, Martínez-Leal JF, Compe E, Coin F, Aviles P, Galmarini CM, Egly JM.

Mol Cancer Ther. 2016 Oct;15(10):2399-2412. Epub 2016 Sep 14.

19.

Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.

Lima M, Bouzid H, Soares DG, Selle F, Morel C, Galmarini CM, Henriques JA, Larsen AK, Escargueil AE.

Oncotarget. 2016 May 3;7(18):25885-901. doi: 10.18632/oncotarget.8292.

20.

Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines.

Ávila-Arroyo S, Nuñez GS, García-Fernández LF, Galmarini CM.

J Breast Cancer. 2015 Dec;18(4):329-38. doi: 10.4048/jbc.2015.18.4.329. Epub 2015 Dec 23.

21.

Unique features of trabectedin mechanism of action.

Larsen AK, Galmarini CM, D'Incalci M.

Cancer Chemother Pharmacol. 2016 Apr;77(4):663-71. doi: 10.1007/s00280-015-2918-1. Epub 2015 Dec 14. Review.

PMID:
26666647
22.

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin.

Colmegna B, Uboldi S, Frapolli R, Licandro SA, Panini N, Galmarini CM, Badri N, Spanswick VJ, Bingham JP, Kiakos K, Erba E, Hartley JA, D'Incalci M.

Br J Cancer. 2015 Dec 22;113(12):1687-93. doi: 10.1038/bjc.2015.407. Epub 2015 Dec 3.

23.

Elisidepsin Interacts Directly with Glycosylceramides in the Plasma Membrane of Tumor Cells to Induce Necrotic Cell Death.

Molina-Guijarro JM, García C, Macías Á, García-Fernández LF, Moreno C, Reyes F, Martínez-Leal JF, Fernández R, Martínez V, Valenzuela C, Lillo MP, Galmarini CM.

PLoS One. 2015 Oct 16;10(10):e0140782. doi: 10.1371/journal.pone.0140782. eCollection 2015.

24.

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.

Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, del Carmen García-Macías M, Sevillano V, Alonso D, Pascual-Pasto G, San-Segundo L, Vila-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J, de Álava E.

Oncotarget. 2015 Aug 7;6(22):18875-90. doi: 10.18632/oncotarget.4303. Erratum in: Oncotarget. 2017 Jun 27;8(26):43592.

25.

Survivorship in untreated breast cancer patients.

Galmarini CM, Tredan O, Galmarini FC.

Med Oncol. 2015 Feb;32(2):466. doi: 10.1007/s12032-014-0466-x. Epub 2015 Jan 15. Review.

PMID:
25588926
26.

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.

D'Incalci M, Badri N, Galmarini CM, Allavena P.

Br J Cancer. 2014 Aug 12;111(4):646-50. doi: 10.1038/bjc.2014.149. Epub 2014 Apr 22. Review.

27.

PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors.

Martínez-Díez M, Guillén-Navarro MJ, Pera B, Bouchet BP, Martínez-Leal JF, Barasoain I, Cuevas C, Andreu JM, García-Fernández LF, Díaz JF, Avilés P, Galmarini CM.

Biochem Pharmacol. 2014 Apr 1;88(3):291-302. doi: 10.1016/j.bcp.2014.01.026. Epub 2014 Jan 31.

PMID:
24486569
28.

Trabectedin and plitidepsin: drugs from the sea that strike the tumor microenvironment.

Galmarini CM, D'Incalci M, Allavena P.

Mar Drugs. 2014 Jan 27;12(2):719-33. doi: 10.3390/md12020719. Review.

29.

Concomitant resistance and early-breast cancer: should we change treatment strategies?

Galmarini CM, Tredan O, Galmarini FC.

Cancer Metastasis Rev. 2014 Mar;33(1):271-83. doi: 10.1007/s10555-013-9449-1. Review.

PMID:
24346157
30.

Hypoxia reduces the efficiency of elisidepsin by inhibiting hydroxylation and altering the structure of lipid rafts.

Király A, Váradi T, Hajdu T, Rühl R, Galmarini CM, Szöllősi J, Nagy P.

Mar Drugs. 2013 Dec 2;11(12):4858-75. doi: 10.3390/md11124858.

31.

Mode of action of trabectedin in myxoid liposarcomas.

Di Giandomenico S, Frapolli R, Bello E, Uboldi S, Licandro SA, Marchini S, Beltrame L, Brich S, Mauro V, Tamborini E, Pilotti S, Casali PG, Grosso F, Sanfilippo R, Gronchi A, Mantovani R, Gatta R, Galmarini CM, Sousa-Faro JM, D'Incalci M.

Oncogene. 2014 Oct 30;33(44):5201-10. doi: 10.1038/onc.2013.462. Epub 2013 Nov 11.

PMID:
24213580
32.

Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.

Monk BJ, Kaye SB, Poveda A, Herzog TJ, Aracil M, Nieto A, Badri N, Parekh TV, Tanović A, Galmarini CM.

Gynecol Oncol. 2014 Jan;132(1):176-80. doi: 10.1016/j.ygyno.2013.10.032. Epub 2013 Nov 5.

PMID:
24211400
33.

Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway.

Martínez S, Pérez L, Galmarini CM, Aracil M, Tercero JC, Gago F, Albella B, Bueren JA.

Br J Pharmacol. 2013 Oct;170(4):871-82. doi: 10.1111/bph.12331.

34.

New interfacial microtubule inhibitors of marine origin, PM050489/PM060184, with potent antitumor activity and a distinct mechanism.

Pera B, Barasoain I, Pantazopoulou A, Canales A, Matesanz R, Rodriguez-Salarichs J, García-Fernandez LF, Moneo V, Jiménez-Barbero J, Galmarini CM, Cuevas C, Peñalva MA, Díaz JF, Andreu JM.

ACS Chem Biol. 2013 Sep 20;8(9):2084-94. doi: 10.1021/cb400461j. Epub 2013 Aug 1.

PMID:
23859655
35.

c-Jun N-terminal kinase phosphorylation is a biomarker of plitidepsin activity.

Muñoz-Alonso MJ, Álvarez E, Guillén-Navarro MJ, Pollán M, Avilés P, Galmarini CM, Muñoz A.

Mar Drugs. 2013 May 21;11(5):1677-92. doi: 10.3390/md11051677.

36.

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).

Romano M, Frapolli R, Zangarini M, Bello E, Porcu L, Galmarini CM, García-Fernández LF, Cuevas C, Allavena P, Erba E, D'Incalci M.

Int J Cancer. 2013 Nov;133(9):2024-33. doi: 10.1002/ijc.28213. Epub 2013 May 25.

37.

Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound.

Serova M, de Gramont A, Bieche I, Riveiro ME, Galmarini CM, Aracil M, Jimeno J, Faivre S, Raymond E.

Mar Drugs. 2013 Mar 20;11(3):944-59. doi: 10.3390/md11030944.

38.

Role of macrophage targeting in the antitumor activity of trabectedin.

Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P.

Cancer Cell. 2013 Feb 11;23(2):249-62. doi: 10.1016/j.ccr.2013.01.008.

39.

Expression of XPG protein in human normal and tumor tissues.

Aracil M, Dauffenbach LM, Diez MM, Richeh R, Moneo V, Leal JF, Fernández LF, Kerfoot CA, Galmarini CM.

Int J Clin Exp Pathol. 2013;6(2):199-211. Epub 2013 Jan 15.

40.

Cancer chemotherapy: a critical analysis of its 60 years of history.

Galmarini D, Galmarini CM, Galmarini FC.

Crit Rev Oncol Hematol. 2012 Nov;84(2):181-99. doi: 10.1016/j.critrevonc.2012.03.002. Epub 2012 Apr 28.

PMID:
22542531
41.

The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.

Morande PE, Zanetti SR, Borge M, Nannini P, Jancic C, Bezares RF, Bitsmans A, González M, Rodríguez AL, Galmarini CM, Gamberale R, Giordano M.

Invest New Drugs. 2012 Oct;30(5):1830-40. doi: 10.1007/s10637-011-9740-3. Epub 2011 Sep 2.

PMID:
21887502
42.

XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids.

Feuerhahn S, Giraudon C, Martínez-Díez M, Bueren-Calabuig JA, Galmarini CM, Gago F, Egly JM.

Chem Biol. 2011 Aug 26;18(8):988-99. doi: 10.1016/j.chembiol.2011.06.007.

43.

βIII-Tubulin is required for interphase microtubule dynamics in untransformed human mammary epithelial cells.

Bouchet BP, Puisieux A, Galmarini CM.

Eur J Cell Biol. 2011 Oct;90(10):872-8. doi: 10.1016/j.ejcb.2011.05.005. Epub 2011 Aug 4.

PMID:
21820201
44.

Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations.

Bueren-Calabuig JA, Giraudon C, Galmarini CM, Egly JM, Gago F.

Nucleic Acids Res. 2011 Oct;39(18):8248-57. doi: 10.1093/nar/gkr512. Epub 2011 Jul 3.

45.

ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment.

Váradi T, Roszik J, Lisboa D, Vereb G, Molina-Guijarro JM, Galmarini CM, Szöllosi J, Nagy P.

Eur J Pharmacol. 2011 Sep 30;667(1-3):91-9. doi: 10.1016/j.ejphar.2011.05.064. Epub 2011 Jun 2.

PMID:
21658382
46.

Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.

Soares DG, Machado MS, Rocca CJ, Poindessous V, Ouaret D, Sarasin A, Galmarini CM, Henriques JA, Escargueil AE, Larsen AK.

Mol Cancer Ther. 2011 Aug;10(8):1481-9. doi: 10.1158/1535-7163.MCT-11-0252. Epub 2011 May 27.

47.

p21(Cip1) regulates cell-substrate adhesion and interphase microtubule dynamics in untransformed human mammary epithelial cells.

Bouchet BP, Fauvet F, Grelier G, Galmarini CM, Puisieux A.

Eur J Cell Biol. 2011 Aug;90(8):631-41. doi: 10.1016/j.ejcb.2011.03.002. Epub 2011 May 11.

PMID:
21561680
48.

Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells.

Molina-Guijarro JM, Macías Á, García C, Muñoz E, García-Fernández LF, David M, Núñez L, Martínez-Leal JF, Moneo V, Cuevas C, Lillo MP, Villalobos Jorge C, Valenzuela C, Galmarini CM.

PLoS One. 2011 Apr 27;6(4):e19042. doi: 10.1371/journal.pone.0019042.

49.

Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.

Colado E, Paíno T, Maiso P, Ocio EM, Chen X, Alvarez-Fernández S, Gutiérrez NC, Martín-Sánchez J, Flores-Montero J, San Segundo L, Garayoa M, Fernández-Lázaro D, Vidriales MB, Galmarini CM, Avilés P, Cuevas C, Pandiella A, San-Miguel JF.

Haematologica. 2011 May;96(5):687-95. doi: 10.3324/haematol.2010.036400. Epub 2011 Feb 17.

50.

Cabazitaxel, a new taxane with favorable properties.

Bouchet BP, Galmarini CM.

Drugs Today (Barc). 2010 Oct;46(10):735-42. doi: 10.1358/dot.2010.46.10.1519019. Review.

PMID:
21076710

Supplemental Content

Loading ...
Support Center